MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

被引：0
|
作者：
Neil Portman
Heloisa H. Milioli
Sarah Alexandrou
Rhiannon Coulson
Aliza Yong
Kristine J. Fernandez
Kee Ming Chia
Ensar Halilovic
Davendra Segara
Andrew Parker
Sue Haupt
Ygal Haupt
Wayne D. Tilley
Alex Swarbrick
C. Elizabeth Caldon
Elgene Lim
机构：
[1] Garvan Institute of Medical Research,St. Vincent’s Clinical School, Faculty of Medicine
[2] University of New South Wales Sydney,Tumor Suppression Laboratory
[3] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology
[4] The University of Melbourne,Adelaide Medical School
[5] Novartis Institutes of Biomedical Research,undefined
[6] The University of Adelaide,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
Breast cancer; MDM2; Oestrogen receptor; CDK4/6 inhibitor; p53;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] CDK4 inhibition diminishes p53 activation by MDM2 antagonists
    Sriraman, Anusha
    Dickmanns, Antje
    Najafova, Zeynab
    Johnsen, Steven A.
    Dobbelstein, Matthias
    CELL DEATH & DISEASE, 2018, 9
  • [32] CDK4 inhibition diminishes p53 activation by MDM2 antagonists
    Anusha Sriraman
    Antje Dickmanns
    Zeynab Najafova
    Steven A. Johnsen
    Matthias Dobbelstein
    Cell Death & Disease, 9
  • [33] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [34] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    María Jimena Rodriguez
    María Cecilia Perrone
    Marina Riggio
    Marta Palafox
    Valeria Salinas
    Andrés Elia
    Natali Daiana Salgueiro
    Andrea Eugenia Werbach
    María Paula Marks
    Marcelo A. Kauffman
    Luciano Vellón
    Violeta Serra
    Virginia Novaro
    Scientific Reports, 13
  • [35] Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors
    Cruz, Marcelo R.
    Limentani, Kimberly
    Taxter, Timothy
    Santa-Maria, Cesar A.
    Behdad, Amir
    Gradishar, William J.
    Nagy, Rebecca J.
    Cristofanilli, Massimo
    CANCER RESEARCH, 2018, 78 (04)
  • [36] MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
    Vilgelm, Anna E.
    Saleh, Nabil
    Shattuck-Brandt, Rebecca
    Riemenschneider, Kelsie
    Slesur, Lauren
    Chen, Sheau-Chiann
    Johnson, C. Andrew
    Yang, Jinming
    Blevins, Ashlyn
    Yan, Chi
    Johnson, Douglas B.
    Al-Rohil, Rami N.
    Halilovic, Ensar
    Kauffmann, Rondi M.
    Kelley, Mark
    Ayers, Gregory D.
    Richmond, Ann
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (505)
  • [37] Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
    Liu, Ying
    Zhang, Ning
    Zhang, Hanwen
    Wang, Lijuan
    Duan, Yi
    Wang, Xiaolong
    Chen, Tong
    Liang, Yiran
    Li, Yaming
    Song, Xiaojin
    Li, Chen
    Han, Dianwen
    Chen, Bing
    Zhao, Wenjing
    Yang, Qifeng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3535 - 3545
  • [38] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    Rodriguez, Maria Jimena
    Perrone, Maria Cecilia
    Riggio, Marina
    Palafox, Marta
    Salinas, Valeria
    Elia, Andres
    Salgueiro, Natali Daiana
    Werbach, Andrea Eugenia
    Marks, Maria Paula
    Kauffman, Marcelo A.
    Vellon, Luciano
    Serra, Violeta
    Novaro, Virginia
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [39] Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
    Karimi, Leena
    Alves, Carla L.
    Terp, Mikkel G.
    Tuttolomondo, Martina
    Portman, Neil
    Ehmsen, Sidse
    Johansen, Lene E.
    Bak, Martin
    Lim, Elgene
    Ditzel, Henrik J.
    CANCER COMMUNICATIONS, 2023, 43 (06) : 720 - 725
  • [40] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
12345